ALK-Abello A/S
CSE:ALK B
ALK-Abello A/S
Total Assets
ALK-Abello A/S
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
ALK-Abello A/S
CSE:ALK B
|
Total Assets
kr6.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
||
Novo Nordisk A/S
CSE:NOVO B
|
Total Assets
kr397.4B
|
CAGR 3-Years
32%
|
CAGR 5-Years
26%
|
CAGR 10-Years
19%
|
||
H Lundbeck A/S
CSE:HLUN A
|
Total Assets
kr37.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
S
|
Stenocare A/S
CSE:STENO
|
Total Assets
kr37.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
ALK-Abello A/S
Glance View
ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.
See Also
What is ALK-Abello A/S's Total Assets?
Total Assets
6.7B
DKK
Based on the financial report for Dec 31, 2023, ALK-Abello A/S's Total Assets amounts to 6.7B DKK.
What is ALK-Abello A/S's Total Assets growth rate?
Total Assets CAGR 5Y
7%
Over the last year, the Total Assets growth was 7%. The average annual Total Assets growth rates for ALK-Abello A/S have been 7% over the past three years , 7% over the past five years .